


CLINICAL TRIAL

2013-005393-22

Retinal RED



A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin : Retinol Acyltransferase (LRAT)

Rare Eye Disease concerned by the trial :
Retinitis pigmentosa; Inherited Retinal Disease
caused by Mutation in RPE65 or LRAT genes

Status of the trial : not yet recruiting
Orphan drug recognition : Yes

Inclusion criteria : [click here to see detailed criteria](#)

Exclusion criteria : [click here to see detailed criteria](#)



Inclusion
opening date : 06/09/2016



Inclusion closing
date (previsional) : 06/09/2019

Children



Adults



Within ERN-EYE members



Principal location of the trial :

**Center for Ophthalmology, University of
Tübingen**

Elfriede-Aulhorn-Str. 7
72076 Tübingen
Germany

[Contact details](#)




Principal investigator name :

Eberhart Zrenner



Other investigators :

not known yet



Funder type : Drug company - Industry

[More informations](#)